Raydiant Oximetry, a San Ramon, CA-based clinical-stage medical device company, raised $7.5M in Series A3 Extension funding.
The round was led by Cross-Border Impact Ventures, with participation from RH Capital, Global Health Impact Fund, VCapital and the March of Dimes Innovation Fund.
The company intends to use the funds to support two clinical studies of the LumerahTM and DaisyTM technologies.
Founded by Neil P. Ray, Raydiant Oximetry is a clinical-stage company dedicated to improving outcomes for mothers and babies during childbirth. It has developed two innovative technologies, Lumerah™, a low-cost, non-invasive sensor that continuously monitors fetal oxygenation during labor, and DaisyTM, a novel surgical device designed to quantify blood loss, treat uterine atony and prevent post-partum hemorrhage (PPH) after a C-section delivery.
Both clinical studies are taking place at Eastern Virginia Medical School (EVMS) in Norfolk, Virginia, under the direction of Dr. George Saade, Chair of Obstetrics & Gynecology, Associate Dean for Women’s Health at EVMS and the Editor-in-Chief for the American Journal of Perinatology.
FinSMEs
04/06/2024